Refine
Has Fulltext
- yes (31)
Is part of the Bibliography
- yes (31)
Year of publication
Document Type
- Journal article (28)
- Doctoral Thesis (2)
- Preprint (1)
Keywords
- cancer (3)
- biodiversity (2)
- metagenomics (2)
- microbiome (2)
- Accurate (1)
- Acids (1)
- Annotation (1)
- B cells (1)
- BRAF mutations (1)
- BRN-3A (1)
- Barrier (1)
- Biology (1)
- Bor (1)
- Boron (1)
- COVID-19 (1)
- CRC (1)
- CX5461 (1)
- Cell surface proteomics (1)
- Colonization (1)
- Computational and Systems Biology (1)
- Cytologie (1)
- DEL(5Q) (1)
- DNA (1)
- DNA damage (1)
- DNA methylation (1)
- Diborane (1)
- Differential RNA-sequencing (1)
- Dynamics (1)
- Elektronendichte (1)
- Epicardium-derived cells (1)
- Exziton (1)
- GRAID (1)
- HRQL (1)
- Halbleiterschicht (1)
- Health (1)
- Helicobacter pylori (1)
- Human atrial stromal cells (1)
- Inhibitor (1)
- Lampbrush chromosomes (1)
- MDS (1)
- MIZ1 (1)
- MYC (1)
- Metallocene (1)
- Metallocenes (1)
- Microbiology and Infectious Disease (1)
- NAKO (1)
- NF-KAPPA-B (1)
- Niederdimensionaler Halbleiter (1)
- Optische Spektroskopie (1)
- P53 (1)
- Polarisiertes Licht (1)
- Quantenpunkt (1)
- RNAPOL1 (1)
- Research Article (1)
- SPA-LEED (1)
- STM (1)
- Schlaganfall (1)
- Spindynamik (1)
- Strains (1)
- T cells (1)
- TP53 mutations (1)
- Theoretische Chemie (1)
- Turkish (1)
- Xenopus oocytes (1)
- Zirkularpolarisation (1)
- acculturation (1)
- adsoption (1)
- adult-onset (1)
- allergies (1)
- androgen deprivation therapy (1)
- antibodies (1)
- antidepressants (1)
- antifungal agents (1)
- antifungals (1)
- ants (1)
- anxiety disorders (1)
- apoptosis (1)
- arteriitis temporal arteriitis (1)
- aspergillosis (1)
- assemblages (1)
- asthma (1)
- autoimmune (1)
- azacitidine (1)
- beta-diveristy (1)
- beta-diversity (1)
- birth cohort (1)
- c-reactive protein (1)
- cag pathogenicity island (1)
- campylobacter jejuni infection (1)
- childhood asthma (1)
- children (1)
- chromosome 11Q13 (1)
- circular polarization (1)
- cohort studies (1)
- colorectal cancer (1)
- community data (1)
- complication aortic-aneurysm (1)
- corticosteroid treatment (1)
- cultivation (1)
- delivery mode (1)
- density functional calculations (1)
- dermatitis (1)
- dermatology (1)
- diborenes (1)
- diet (1)
- direct PCR (1)
- dog microbiome (1)
- domain (1)
- double-blind (1)
- ecology (1)
- electron density (1)
- enzyme-linked immunoassays (1)
- epidemiology (1)
- epithelial cells (1)
- erythrocyte sedimentation-rate (1)
- evolution (1)
- exciton (1)
- family (1)
- fatigue (1)
- filaggrin mutations (1)
- food allergy (1)
- gastrointestinal tract (1)
- genomewide association (1)
- gestational age (1)
- gradients (1)
- hay fever (1)
- health-related quality of life (1)
- heart (1)
- heart failure (1)
- hematologic malignancies (1)
- herbivorous insects (1)
- human microbiome (1)
- human mineralocorticoid receptor (1)
- hypthesis (1)
- image correlation spectroscopy (1)
- in situ hybridization (1)
- in-vitro (1)
- in-vivo (1)
- infant growth (1)
- inflammatory diseases (1)
- inhibition (1)
- insects (1)
- invasive candidiasis (1)
- invasive fungal infections (1)
- isolation (1)
- juvenile myoclonic epilepsy (1)
- karyotype (1)
- kidneys (1)
- large-vessel vasculitis (1)
- late-onset (1)
- living cells (1)
- low birth weight (1)
- lymph node metastases (1)
- marine microalgae (1)
- melanoma (1)
- memory B cells (1)
- metastasis-directed therapy (1)
- migrants (1)
- mindfulness (1)
- mobility (1)
- mouse microbiome (1)
- mycoses (1)
- neural crest factors (1)
- nuclear-pore complexes (1)
- ocular manifestations (1)
- offspring (1)
- oligmometastases (1)
- oligorecurrence (1)
- oncogene-induced senescence (1)
- optical spectroscopy (1)
- organoid (1)
- p53 expression (1)
- panic disorder (1)
- passes (1)
- patient-derived organoid (PDOs) (1)
- patient-derived tumor organoid (PDTO) (1)
- patient-reported outcomes (1)
- patterning (1)
- perinatal (1)
- physics (1)
- pig microbiome (1)
- polymyalgia-rheomatica (1)
- prognosis (1)
- prostate cancer (1)
- protein (1)
- psychosocial (1)
- quality of life (1)
- radiation therapy (1)
- reconstruction (1)
- regulatory T cells (1)
- reveals (1)
- rheumatoid arthritis (1)
- ribosome (1)
- risk (1)
- scoring system (1)
- semiconductor quantum dots (1)
- sex (1)
- similarity (1)
- specialization (1)
- species richness (1)
- spindynamic (1)
- stereotactic body radiotherapy (1)
- strained molecules (1)
- strategy (1)
- surface stress (1)
- systemic vasculitides (1)
- taxonomy (1)
- telomere length (1)
- theoretical chemistry (1)
- transcription (1)
- transcription units (1)
- treatment guidelines (1)
- trees (1)
- tumor disease (1)
- tumourigenesis (1)
- turnover (1)
- vicinal surfaces (1)
- wheezing (1)
- yoga (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (10)
- Institut für Klinische Epidemiologie und Biometrie (4)
- Medizinische Klinik und Poliklinik II (4)
- Pathologisches Institut (3)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (2)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (2)
- Neurologische Klinik und Poliklinik (2)
- Physikalisches Institut (2)
- Comprehensive Cancer Center Mainfranken (1)
- Institut für Anorganische Chemie (1)
Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. Early antifungal treatment is mandatory to improve survival. Today, a number of effective and better-tolerated but more expensive antifungal agents compared to the former gold standard amphotericin B deoxycholate are available. Clinical decision-making must consider results from numerous studies and published guidelines, as well as licensing status and cost pressure. New developments in antifungal prophylaxis improving survival rates result in a continuous need for actualization. The treatment options for invasive Candida infections include fluconazole, voriconazole, and amphotericin B and its lipid formulations, as well as echinocandins. Voriconazole, amphotericin B, amphotericin B lipid formulations, caspofungin, itraconazole, and posaconazole are available for the treatment of invasive aspergillosis. Additional procedures, such as surgical interventions, immunoregulatory therapy, and granulocyte transfusions, have to be considered. The Infectious Diseases Working Party of the German Society of Hematology and Oncology here presents its 2008 recommendations discussing the dos and do-nots, as well as the problems and possible solutions, of evidence criteria selection.
Theoretical Investigations on the Interactions of Small Compounds with their Molecular Environments
(2015)
In the first part of this work, a combination of theoretical methods for the rational design of covalent inhibitor is presented. Starting from the crystal structure of the covalent complex of a lead compound, quantum mechanical and QM/MM calculations were used to derive the exact geometry of the preceeding non-covalent enzyme inhibitor complex. The geometry of the latter mainly determines the reactivity of the inhibitor against its target enzyme concerning the formation of the covalent bond towards an active site residue. Therefore, this geometry was used as starting point for the optimization of the substitution pattern of the inhibitor such as to increase its binding affinity without loosing its ability to covalently bind to the target protein. The optimization of the chemical structure was supported by using docking procedures, which are best suited to estimate binding affinities that arise from the introduced changes. A screening of the novel substitution patterns resulted in a first generation of model compounds which were further tested for their reactivity against the target. Dynamic simulations on the novel compounds revealed that the orientation that compounds adopt within the active site are such that a covalent interaction with the enzyme is no longer possible. Hence, the chemical structure was further modified, including not only changes in the substituents but also within the core of the molecule. Docking experiments have been conducted to assure sufficiently high binding affinities and to obtain the most favored binding poses. Those have then again been used for dynamic simulations which resulted in structures, for which the bond formation process appeared feasible. A final series of QM/MM calculations considering various protonation states was computed to estimate the reaction energies for the covalent attachment of the inhibitor to the enzyme. The theoretical results indicate a reasonable high inhibition potency of the novel compounds.
The second part concentrates on the environmental influences on the electron density of an inhibitor molecule. Therefore, a vinylsulfone-based model compound was selected for which an experimental crystal structure for the pure compound as well as a theoretically determined enzyme-inhibitor complex have been available. To provide reference data for the larger systems, the conformational space of the isolated molecule was screened for favorable geometries which were later compared to those within the crystal and protein surrounding. The geometry of the crystal structure could readily be taken from the experimental data whereas calculations on the protein complex revealed four potential non-covalent complexes exhibiting different arrangements of the molecule within the active site of the protein as well as two possible protonation states of the catalytic dyad. Hence, all four protein complexes have been compared to the crystal structure of the molecule as well as against the more favorable geometries of the isolated molecule being determined within vacuum or aqueous surrounding. Whereas the molecule itself was found to adopt comparable geometries within all investigated environments, the interactions pattern between the crystal surrounding and the protein differed largely from each other. The favorable formation of dimers within the crystal has a strong stabilizing effect and explains the extraordinarily good quality of the crystal. Within the protein however, repulsive forces have been found between the protein and the inhibitor. The origin of the repulsion could be traced back to effect of on of the substituents to the vinyl scaffold. The difference in the chemical structure in comparison to a well known inhibitor might also explain the experimentally found loss of activity for the model compound in comparison to K11777.
Pigment cells and neuronal cells both are derived from the neural crest. Here, we describe the Pit-Oct-Unc (POU) domain transcription factor Brn3a, normally involved in neuronal development, to be frequently expressed in melanoma, but not in melanocytes and nevi. RNAi-mediated silencing of Brn3a strongly reduced the viability of melanoma cell lines and decreased tumour growth in vivo. In melanoma cell lines, inhibition of Brn3a caused DNA double-strand breaks as evidenced by Mre11/Rad50-containing nuclear foci. Activated DNA damage signalling caused stabilization of the tumour suppressor p53, which resulted in cell cycle arrest and apoptosis. When Brn3a was ectopically expressed in primary melanocytes and fibroblasts, anchorage-independent growth was increased. In tumourigenic melanocytes and fibroblasts, Brn3a accelerated tumour growth in vivo. Furthermore, Brn3a cooperated with proliferation pathways such as oncogenic BRAF, by reducing oncogene-induced senescence in non-malignant melanocytes. Together, these results identify Brn3a as a new factor in melanoma that is essential for melanoma cell survival and that promotes melanocytic transformation and tumourigenesis.
Background: Giant cell arteritis (GCA) is the most common systemic vasculitis in persons aged 50 and above (incidence, 3.5 per 100 000 per year). It affects cranial arteries, the aorta, and arteries elsewhere in the body, e.g., in the limbs.
Methods: We selectively review the pertinent literature, including guidelines and recommendations from Germany and abroad.
Results: The typical symptoms of new-onset GCA are bi-temporal headaches, jaw claudiacation, scalp tenderness, visual disturbances, systemic symptoms such as fever and weight loss, and polymyalgia. The diagnostic assessment comprises laboratory testing (erythrocyte sedimentation rate, C-reactive protein), imaging studies (duplex sonography, high-resolution magnetic resonance imaging, positron-emission tomography), and temporal artery biopsy. The standard treatment is with corticosteroids (adverse effects: diabetes mellitus, osteoporosis, cataract, arterial hypertension). A meta-analysis of three randomized controlled trials led to a recommendation for treatment with methotrexate to lower the recurrence rate and spare steroids. Patients for whom methotrexate is contraindicated or who cannot tolerate the drug can be treated with azathioprine instead.
Conclusion: Giant cell arteritis, if untreated, progresses to involve the aorta and its collateral branches, leading to various complications. Late diagnosis and treatment can have serious consequences, including irreversible loss of visual function.
Background
Gut microbes influence their hosts in many ways, in particular by modulating the impact of diet. These effects have been studied most extensively in humans and mice. In this work, we used whole genome metagenomics to investigate the relationship between the gut metagenomes of dogs, humans, mice, and pigs.
Results
We present a dog gut microbiome gene catalog containing 1,247,405 genes (based on 129 metagenomes and a total of 1.9 terabasepairs of sequencing data). Based on this catalog and taxonomic abundance profiling, we show that the dog microbiome is closer to the human microbiome than the microbiome of either pigs or mice. To investigate this similarity in terms of response to dietary changes, we report on a randomized intervention with two diets (high-protein/low-carbohydrate vs. lower protein/higher carbohydrate). We show that diet has a large and reproducible effect on the dog microbiome, independent of breed or sex. Moreover, the responses were in agreement with those observed in previous human studies.
Conclusions
We conclude that findings in dogs may be predictive of human microbiome results. In particular, a novel finding is that overweight or obese dogs experience larger compositional shifts than lean dogs in response to a high-protein diet.
Introduction:
Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin’s lymphoma in a real-life clinical setting.
Methods:
Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.
Results:
A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician’s visual analogue scale; mean improvement from baseline of 12.1 mm)
Ribosomal biogenesis and protein synthesis are deregulated in most cancers, suggesting that interfering with translation machinery may hold significant therapeutic potential. Here, we show that loss of the tumor suppressor adenomatous polyposis coli (APC), which constitutes the initiating event in the adenoma carcinoma sequence for colorectal cancer (CRC), induces the expression of RNA polymerase I (RNAPOL1) transcription machinery, and subsequently upregulates ribosomal DNA (rDNA) transcription. Targeting RNAPOL1 with a specific inhibitor, CX5461, disrupts nucleolar integrity, and induces a disbalance of ribosomal proteins. Surprisingly, CX5461-induced growth arrest is irreversible and exhibits features of senescence and terminal differentiation. Mechanistically, CX5461 promotes differentiation in an MYC-interacting zinc-finger protein 1 (MIZ1)- and retinoblastoma protein (Rb)-dependent manner. In addition, the inhibition of RNAPOL1 renders CRC cells vulnerable towards senolytic agents. We validated this therapeutic effect of CX5461 in murine- and patient-derived organoids, and in a xenograft mouse model. These results show that targeting ribosomal biogenesis together with targeting the consecutive, senescent phenotype using approved drugs is a new therapeutic approach, which can rapidly be transferred from bench to bedside.
Recently reported insect declines have raised both political and social concern. Although the declines have been attributed to land use and climate change, supporting evidence suffers from low taxonomic resolution, short time series, a focus on local scales, and the collinearity of the identified drivers. In this study, we conducted a systematic assessment of insect populations in southern Germany, which showed that differences in insect biomass and richness are highly context dependent. We found the largest difference in biomass between semi-natural and urban environments (-42%), whereas differences in total richness (-29%) and the richness of threatened species (-56%) were largest from semi-natural to agricultural environments. These results point to urbanization and agriculture as major drivers of decline. We also found that richness and biomass increase monotonously with increasing temperature, independent of habitat. The contrasting patterns of insect biomass and richness question the use of these indicators as mutual surrogates. Our study provides support for the implementation of more comprehensive measures aimed at habitat restoration in order to halt insect declines.
Objective
The current article encompasses a literature review and recommendations for radiotherapy in nodal oligorecurrent prostate cancer.
Materials and methods
A literature review focused on studies comparing metastasis-directed stereotactic ablative radiotherapy (SABR) vs. external elective nodal radiotherapy (ENRT) and studies analyzing recurrence patterns after local nodal treatment was performed. The DEGRO Prostate Cancer Expert Panel discussed the results and developed treatment recommendations.
Results
Metastasis-directed radiotherapy results in high local control (often > 90% within a follow-up of 1–2 years) and can be used to improve progression-free survival or defer androgen deprivation therapy (ADT) according to prospective randomized phase II data. Distant progression after involved-node SABR only occurs within a few months in the majority of patients. ENRT improves metastases-free survival rates with increased toxicity in comparison to SABR according to retrospective comparative studies. The majority of nodal recurrences after initial local treatment of pelvic nodal metastasis are detected within the true pelvis and common iliac vessels.
Conclusion
ENRT with or without a boost should be preferred to SABR in pelvic nodal recurrences. In oligometastatic prostate cancer with distant (extrapelvic) nodal recurrences, SABR alone can be performed in selected cases. Application of additional systemic treatments should be based on current guidelines, with ADT as first-line treatment for hormone-sensitive prostate cancer. Only in carefully selected patients can radiotherapy be initially used without additional ADT outside of the current standard recommendations. Results of (randomized) prospective studies are needed for definitive recommendations.